By Ben Glickman


Amgen on Thursday received approval from U.S. regulators for its drug to treat a form of late-stage lung-cancer.

The pharmaceutical company said that Imdelltra, an immunotherapy, was approved by the U.S. Food and Drug Administration for treating adults with extensive-stage small-cell lung cancer.

The indication is specifically for cases with progression on or after platinum-based chemotherapy.

Amgen's treatment received accelerated approval, meaning it was approved based on a surrogate endpoint in a trial.


Write to Ben Glickman at ben.glickman@wsj.com


(END) Dow Jones Newswires

05-16-24 1921ET